Rosetta Genomics’ FISH Testing Services to Be Used in Prostate Cancer Study

Rosetta Genomics’ FISH Testing Services to Be Used in Prostate Cancer Study
Rosetta Genomics announced the signing of a service agreement with an unnamed global pharmaceutical, under which it will provide Fluorescence in situ Hybridization (FISH) testing services for use by that company in a clinical trial it is conducting in prostate cancer (PC). The study will use FISH to find the phosphatase and tensin homolog (PTEN) gene status in a

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *